Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin

Authors: Angelo Pietro Femia, Piero Dolara, Maddalena Salvadori, Giovanna Caderni

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Colon cancer stem cells may drive carcinogenesis and account for chemotherapeutic failure. Although many markers for these cells have been proposed, there is no complete agreement regarding them, nor has their presence in the early phases of carcinogenesis been characterized in depth.

Methods

The expression of the putative markers LGR-5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), MSI-1 (Musashi-1) and DCAMKL-1 (doublecortin and calcium/calmodulin-dependent protein kinase-like-1) was studied in normal colon mucosa (NM), in the precancerous lesions Mucin Depleted Foci (MDF) and in macroscopic tumours (adenomas) of 1,2-dimethylhydrazine-treated rats. Co-localization between these markers and nuclear β-catenin (NBC), an attributed feature of cancer stem cells, was also determined. Moreover, since PGE2 could increase NBC, we tested whether short-term treatment with celecoxib, a COX-2 inhibitor (2 weeks, 250 ppm in the diet) could reduce the expression of these markers.

Results

LGR-5 expression in NM was low (Labelling Index (LI): 0.22±0.03 (means±SE)) with positive cells located mainly at the base of the crypts. Compared to NM, LGR-5 was overexpressed in MDF and tumours (LI: 4.7±2.0 and 2.9±1.0 in MDF and tumours, respectively, P<0.01 compared to NM). DCAMKL-1 positive cells, distributed along the length of normal crypts, were reduced in MDF and tumours. Nuclear expression of MSI-1, located mainly at the base of normal crypts, was not observed in MDF or tumours. In both MDF and tumours, few cells co-expressed LGR-5 and NBC (LI: 1.0±0.3 and 0.4±0.2 in MDF and tumours, respectively). Notwithstanding the lower expression of DCAMKL-1 in tumours, the percentage of cells co-expressing DCAMKL-1 and NBC was higher than in NM (LI: 0.5±0.1 and 0.04±0.02 in tumours and NM, respectively). MSI-1 and NBC co-localization was not observed. Celecoxib did not reduce cells co-expressing LGR-5 and NBC.

Conclusions

Based on its prevalent localization at the base of normal crypts, as expected for stem cells, and on the overexpression in precancerous lesions and tumours, we support LGR-5, but not MSI-1 or DCAMKL-1, as putative neoplastic stem cell marker. In both MDF and tumours, we identified LGR-5-positive cells co-expressing NBC which could be a subpopulation with the highest stem cell features.
Appendix
Available only for authorised users
Literature
1.
Todaro M, Francipane MG, Medema JP, Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010, 138 (6): 2151-62. 10.1053/j.gastro.2009.12.063.CrossRefPubMed
2.
Marshman E, Booth C, Potten CS: The intestinal epithelial stem cell. Bioessays. 2002, 24 (1): 91-8. 10.1002/bies.10028.CrossRefPubMed
3.
4.
Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP: Cancer stem cells—old concepts, new insights. Cell Death Differ. 2008, 15 (6): 947-58. 10.1038/cdd.2008.20.CrossRefPubMed
5.
Corpet DE, Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 2005, 41: 1911-22. 10.1016/j.ejca.2005.06.006.CrossRefPubMed
6.
Femia AP, Caderni G: Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products. Planta Med. 2008, 74 (13): 1602-7. 10.1055/s-2008-1074577.CrossRefPubMed
7.
Femia AP, Bendinelli B, Giannini A, Salvadori M, Pinzani P, Dolara P, Caderni G: Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int J Cancer. 2005, 116 (1): 9-15. 10.1002/ijc.20981.CrossRefPubMed
8.
Femia AP, Dolara P, Giannini A, Salvadori M, Biggeri A, Caderni G: Frequent mutation of Apc gene in rat colon tumours and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res. 2007, 67 (2): 445-9. 10.1158/0008-5472.CAN-06-3861.CrossRefPubMed
9.
Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006, 5 (12): 997-1014. 10.1038/nrd2154.CrossRefPubMed
10.
Le NH, Franken P, Fodde R: Tumour -stroma interactions in colorectal cancer: converging on β-catenin activation and cancer stemness. Br J Cancer. 2008, 98 (12): 1886-93. 10.1038/sj.bjc.6604401.CrossRefPubMedPubMedCentral
11.
Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010, 12 (5): 468-76. 10.1038/ncb2048.CrossRefPubMed
12.
Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007, 19 (2): 150-8. 10.1016/j.ceb.2007.02.007.CrossRefPubMed
13.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science. 2005, 310 (5753): 1504-10. 10.1126/science.1116221.CrossRefPubMed
14.
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007, 104 (24): 10158-63. 10.1073/pnas.0703478104.CrossRefPubMedPubMedCentral
15.
Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008, 14 (21): 6751-60. 10.1158/1078-0432.CCR-08-1034.CrossRefPubMed
16.
Potten CS, Booth C, Tudor GL, Booth D, Brady G, Hurley P, Ashton G, Clarke R, Sakakibara S, Okano H: Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation. 2003, 71 (1): 28-41. 10.1046/j.1432-0436.2003.700603.x.CrossRefPubMed
17.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 2007, 445 (7123): 111-5. 10.1038/nature05384.CrossRefPubMed
18.
May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW: Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells. 2008, 26 (3): 630-7. 10.1634/stemcells.2007-0621.CrossRefPubMed
19.
Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumourigenesis. Cancer Res. 2009, 69 (8): 3382-9. 10.1158/0008-5472.CAN-08-4418.CrossRefPubMedPubMedCentral
20.
Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ: The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumour suppressor. Cell. 2012, 149 (1): 146-58. 10.1016/j.cell.2012.02.042.CrossRefPubMedPubMedCentral
21.
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H: Identification of stem cells in small intestine and colon by marker gene LGR-5. Nature. 2007, 449 (7165): 1003-7. 10.1038/nature06196.CrossRefPubMed
22.
23.
Femia AP, Luceri C, Toti S, Giannini A, Dolara P, Caderni G: Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats. BMC Cancer. 2010, 11: 10-194.
24.
Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, Zon LI: Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009, 136 (6): 1136-47. 10.1016/j.cell.2009.01.015.CrossRefPubMedPubMedCentral
25.
European Community: European Community Regulations on the Care and Use of Laboratory Animals (1986) (Law 86/609/EC.
26.
Femia AP, Caderni G, Bottini C, Salvadori M, Dolara P, Tessitore L: Mucin-depleted foci are modulated by dietary treatments and show deregulation of proliferative activity in carcinogen-treated rodents. Int J Cancer. 2007, 120 (11): 2301-5. 10.1002/ijc.22145.CrossRefPubMed
27.
Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, Clune Y, Collins KJ, Paglierani M, Caderni G: Antitumourigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis. 2002, 23 (11): 1953-60. 10.1093/carcin/23.11.1953.CrossRefPubMed
28.
Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q: Expression of LGR-5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis. 2010, 25 (5): 583-90. 10.1007/s00384-010-0903-z.CrossRefPubMed
29.
Kleist B, Xu L, Li G, Kersten C: Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer. Int J Clin Exp Pathol. 2011, 4 (4): 327-35.PubMedPubMedCentral
30.
Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H: Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009, 457 (7229): 608-11. 10.1038/nature07602.CrossRefPubMed
31.
Uchida H, Yamazaki K, Fukuma M, Yamada T, Hayashida T, Hasegawa H, Kitajima M, Kitagawa Y, Sakamoto M: Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci. 2010, 101 (7): 1731-7. 10.1111/j.1349-7006.2010.01571.x.CrossRefPubMed
32.
Nishimura S, Wakabayashi N, Toyoda K, Kashima K, Mitsufuji S: Expression ofMusashi-1 in human normal colon crypt cells: a possible stem cell marker of human colon epithelium. Dig Dis Sci. 2003, 48 (8): 1523-9. 10.1023/A:1024763723240.CrossRefPubMed
33.
Gerbe F, Brulin B, Makrini L, Legraverend C, Jay P: DCAMKL-1 expression identifies Tuft cells rather than stem cells in the adult mouse intestinal epithelium. Gastroenterology. 2009, 137 (6): 2179-80. 10.1053/j.gastro.2009.06.072.CrossRefPubMed
34.
Gerbe F, van Es JH, Makrini L, Brulin B, Mellitzer G, Robine S, Romagnolo B, Shroyer NF, Bourgaux JF, Pignodel C, Clevers H, Jay P: Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. J Cell Biol. 2011, 192 (5): 767-80. 10.1083/jcb.201010127.CrossRefPubMedPubMedCentral
35.
Nabeyama A, Leblond CP: "Caveolated cells" characterized by deep surface invaginations and abundant filaments in mouse gastro-intestinal epithelia. Am J Anat. 1974, 140 (2): 147-65. 10.1002/aja.1001400203.CrossRefPubMed
36.
Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW: Selective blockade of DCAMKL-1 results in tumour growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology. 2009, 137 (2): 649-59. 10.1053/j.gastro.2009.05.004.CrossRefPubMedPubMedCentral
37.
Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ: Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011, 106 (7): 1340-50. 10.1038/ajg.2011.38.CrossRefPubMedPubMedCentral
38.
Fischer SM, Hawk ET, Lubet RA: Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011, 4 (11): 1728-35. 10.1158/1940-6207.CAPR-11-0166.CrossRef
39.
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012, 367 (17): 1596-606. 10.1056/NEJMoa1207756.CrossRefPubMedPubMedCentral
40.
Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW: Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila). 2011, 4 (1): 161-71. 10.1158/1940-6207.CAPR-10-0021.CrossRefPubMedCentral
41.
Brown WA, Skinner SA, Vogiagis D, O'Brien PE: Inhibition of beta-catenintranslocation in rodent colorectal tumours: a novel explanation for theprotective effect of nonsteroidal antiinflammatory drugs in colorectal cancer. Dig Dis Sci. 2001, 46 (11): 2314-21. 10.1023/A:1012326525692.CrossRefPubMed
42.
Lönnroth C, Andersson M, Nordgren S, Lundholm K: Downregulation of Prominin1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol. 2012, 41 (1): 15-23.PubMed
43.
Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H, Oue N, Yasui W, Clevers H, Schoen RE, Yu J, Zhang L: Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA. 2010, 107 (46): 20027-32. 10.1073/pnas.1010430107.CrossRefPubMedPubMedCentral
44.
Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV: Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res. 2005, 65 (17): 8022-7.PubMed
45.
Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ: Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68 (4): 1213-20. 10.1158/0008-5472.CAN-07-5172.CrossRefPubMed
Metadata
Title
Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin
Authors
Angelo Pietro Femia
Piero Dolara
Maddalena Salvadori
Giovanna Caderni
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-48

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells

Research article

Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications

Research article

Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation

Research article

Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas

Research article

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

Research article

Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits